Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Subcutaneous Depot Leuprorelin

Subcutaneous Depot Leuprorelin Am J Cancer 2004; 3 (3): 203 GUEST COMMENTARIES 1175-6357/04/0003-0203/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. This subcutaneous depot leuprorelin (leuprolide acetate) for- A Viewpoint by Mark Rosenthal mulation is a luteinizing hormone-releasing hormone (LHRH) agonist available for 1-, 3-, or 4-month application. Its pharmaco- Cancer Trials Australia, The Royal Melbourne Hospital, dynamic, pharmacokinetic, and adverse-effect profiles mimic Parkville, Victoria, Australia those of other LHRH agonists. Castration testosterone levels are Hormone therapy for prostate cancer has a history extending achieved in almost 100% of patients by 6–8 months. A transient over 60 years. This form of therapy has a defined role in metastatic increase in testosterone levels is observed within 2–3 days of disease, in the treatment of localized prostate cancer in conjunc- administration, potentially resulting in a ’flare’ phenomenon. tion with irradiation, and in the treatment of locally advanced, node-positive disease. Controversy remains as to the benefits of Thus, care should be exercised in patients with impending spinal combined androgen ablation and the timing of hormone therapy cord compression, ureteric obstruction, or significant tumor bulk, following biochemical disease progression after definitive therapy to ensure that they are not compromised by the introduction of of localized http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Subcutaneous Depot Leuprorelin

American Journal of Cancer , Volume 3 (3) – Aug 10, 2012

Subcutaneous Depot Leuprorelin

Abstract

Am J Cancer 2004; 3 (3): 203 GUEST COMMENTARIES 1175-6357/04/0003-0203/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. This subcutaneous depot leuprorelin (leuprolide acetate) for- A Viewpoint by Mark Rosenthal mulation is a luteinizing hormone-releasing hormone (LHRH) agonist available for 1-, 3-, or 4-month application. Its pharmaco- Cancer Trials Australia, The Royal Melbourne Hospital, dynamic, pharmacokinetic, and adverse-effect profiles mimic Parkville, Victoria,...
Loading next page...
 
/lp/springer-journals/subcutaneous-depot-leuprorelin-0MsuhSNkTH
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403030-00010
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2004; 3 (3): 203 GUEST COMMENTARIES 1175-6357/04/0003-0203/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. This subcutaneous depot leuprorelin (leuprolide acetate) for- A Viewpoint by Mark Rosenthal mulation is a luteinizing hormone-releasing hormone (LHRH) agonist available for 1-, 3-, or 4-month application. Its pharmaco- Cancer Trials Australia, The Royal Melbourne Hospital, dynamic, pharmacokinetic, and adverse-effect profiles mimic Parkville, Victoria, Australia those of other LHRH agonists. Castration testosterone levels are Hormone therapy for prostate cancer has a history extending achieved in almost 100% of patients by 6–8 months. A transient over 60 years. This form of therapy has a defined role in metastatic increase in testosterone levels is observed within 2–3 days of disease, in the treatment of localized prostate cancer in conjunc- administration, potentially resulting in a ’flare’ phenomenon. tion with irradiation, and in the treatment of locally advanced, node-positive disease. Controversy remains as to the benefits of Thus, care should be exercised in patients with impending spinal combined androgen ablation and the timing of hormone therapy cord compression, ureteric obstruction, or significant tumor bulk, following biochemical disease progression after definitive therapy to ensure that they are not compromised by the introduction of of localized

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.